Boehringer Ingelheim said today that it will pay $650 million in a “comprehensive settlement” of lawsuits over Pradaxa (dabigatran), the company’s novel anticoagulant. The company said that it expects the settlement will resolve about 4,000 current cases against the company in the US.
…
Click here to read the full post on Forbes.
Thank you for scrutinizing the clinical trials processes of the FDA. In case you missed it, the Project On Government Oversight just published a report on dangerous decision making at the FDA, focusing on the agency’s handling of (the blood-thinner) Pradaxa: http://www.pogo.org/our-work/reports/2015/drug-problems-dangerous-fda-decision-making.html